Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19
The global pandemic of SARS-CoV-2, the causative viral pathogen of COVID-19, has driven
the biomedical community to action—to uncover and develop antiviral interventions. One …
the biomedical community to action—to uncover and develop antiviral interventions. One …
Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
LJ Stevens, AJ Pruijssers, HW Lee… - Science translational …, 2022 - science.org
The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
KT Choy, AYL Wong, P Kaewpreedee, SF Sia, D Chen… - Antiviral research, 2020 - Elsevier
Highlights•Remdesivir inhibits SARS-CoV-2 replication in Vero-E6 cells with EC 50 at 23.15
μM.•Lopinavir but not ritonavir inhibits SARS-CoV-2 replication with EC 50 at 26.63 μM.• …
μM.•Lopinavir but not ritonavir inhibits SARS-CoV-2 replication with EC 50 at 26.63 μM.• …
[HTML][HTML] SARS-CoV-2 vaccines: status report
F Amanat, F Krammer - Immunity, 2020 - cell.com
SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since
infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here …
infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here …
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
G Li, E De Clercq - Nature reviews Drug discovery, 2020 - nature.com
Therapeutic options for the 2019 novel coronavirus (2019-nCoV) Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …
you for visiting nature.com. You are using a browser version with limited support for CSS. To …
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease
outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative …
outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative …
[HTML][HTML] An overview of COVID-19
Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection emerged in Wuhan City, Hubei Province, China in December 2019. By Feb. 11 …
infection emerged in Wuhan City, Hubei Province, China in December 2019. By Feb. 11 …
Remdesivir for the treatment of Covid-19—preliminary report
BACKGROUND: Although several therapeutic agents have been evaluated for the treatment
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be …
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials
Background Interpretation of the evidence from randomised controlled trials (RCTs) of
remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …
remdesivir in patients treated in hospital for COVID-19 is conflicting. We aimed to assess the …